VIROLOGICAL RESPONSE AND TOLERANCE TO BOCEPREVIR OR TELAPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN TRIPLE THERAPY IN HIV-HCV CO-INFECTED PATIENTS: REAL-LIFE FINDINGS FROM THE PAN STUDY

被引：0

作者：

Baumgarten, A. ^{[1
]}

Holm, S. ^{[2
]}

Lutz, T. ^{[3
]}

Schranz, D. ^{[4
]}

Mauss, S. ^{[5
]}

Hillenbrand, H. ^{[6
]}

Moll, A. ^{[7
]}

Scholten, S. ^{[8
]}

Schmidt, W. ^{[9
]}

Goelz, J. ^{[10
]}

Hintsche, B. ^{[11
]}

Schleehauf, D. ^{[10
]}

Fenske, S. ^{[12
]}

Stephan, C. ^{[13
]}

Prziwara, D. ^{[14
]}

Koeppe, S.

Alshuth, U. ^{[15
]}

Jaeger, H. ^{[16
]}

机构：

[1] Mib Dienstleistung GmbH, Berlin, Germany

[2] Private Practice Dres Kuhlmann Holm Heiken, Hannover, Germany

[3] Infektiologikum, Frankfurt, Germany

[4] Private Practice Dres Schranz Fischer, Berlin, Germany

[5] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany

[6] Ctr Med, City Ost, Germany

[7] Ctr HIV & Hepatol, Berlin, Germany

[8] Ctr Med Hohenstaufenring, Cologne, Germany

[9] Praxiszentrum Kaiserdamm, MVZ Aerzteforum Seestrasse, Berlin, Germany

[10] Praxiszentrum Kaiserdamm, Ctr Addict Med Hepatol & HIV, Berlin, Germany

[11] Ctr Infectiol & Hepatol, Berlin, Germany

[12] ICH Grindelpraxis, Infekt Epidemiol Ctr, Hamburg, Germany

[13] JW Goethe Univ Hosp, Dept Infect Dis, Frankfurt, Germany

[14] Praxisteam Mitte, Berlin, Germany

[15] Roche Pharma AG, Virol, Grenzach Wyhlen, Germany

[16] MVZ Karlsplatz, HIV Res & Clin Care Ctr, Munich, Germany

来源：

JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期

关键词：

D O I：

10.1016/S0168-8278(14)61306-4

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P1146

引用

页码：S464 / S464

页数：1

共 50 条

[21] Triple Therapy Under Real Life Conditions: Telaprevir (TVR) and Boceprevir (BOC) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1. the PAN Study
Moog, Gero
Mauss, Stefan
Hueppe, Dietrich
Spengler, Ulrich
Schott, Eckart
Eisenbach, Christoph
Schober, Andreas
Heyne, Renate
Jung, Maria-Christina
Teuber, Gerlinde
Doss, Margareta Frank
Roessle, Martin
Pape, Stefan
Schuchmann, Marcus
Alshuth, Ulrich
Buggisch, Peter
GASTROENTEROLOGY, 2013, 144 (05) : S980 - S980
[22] Outcomes in HIV-HCV co-infected genotype 1 patients treated with peginterferon alfa-2a (400) plus ribavirin (RBV) 1000/1200 mg/d: Predictions based on a generalized additive model (GAM)
Torriani, Francesca
Rodriguez-Torres, Maribel
Rockstroh, Juergen
Snoeck, Eric
Jorga, Karin
Dieterick, Douglas T.
HEPATOLOGY, 2007, 46 (04) : 831A - 831A
[23] Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman
Hasson, Hamid
Messina, Emanuela
Merli, Marco
Della Torre, Liviana
Morsica, Giulia
Bagaglio, Sabrina
Lazzarin, Adriano
Uberti-Foppa, Caterina
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 29 : 100 - 102
[24] Safety and efficacy of peginterferon alfa-2a (40kd) (Pegasys®) plus ribavirin (Copegus®) in HIV-HCV co-infected patients with cirrhosis/bridging fibrosis:: Results of the AIDS Pegasys Ribavirin International Co-Infection Trial (APRICOT)
Sasadeusz, J
Godofsky, E
Sterling, R
Clotet, B
Soriano, V
Rieger, A
Torriani, F
Depamphilis, J
HEPATOLOGY, 2004, 40 (04) : 326A - 326A
[25] Multicenter pilot study to assess the efficacy and safety of prolonging treatment with peginterferon alfa 2 a (Pegasys) and ribavirin (Copegus) in HIV and HCV co-infected patients without early virological response
Planas, R
Foster, D
González, J
Force, L
Cervantes, M
Vilaró, J
Roget, M
García, I
Pedrol, E
Tor, J
Ballesteros, AL
Hombrados, M
Salas, A
Rubio, M
Sirera, G
Clotet, B
Tural, C
GASTROENTEROLOGY, 2005, 128 (04) : A682 - A682
[26] Patients with HCV/HIV co-infection achieving a sustained virological response following HCV treatment with peginterferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS) have improved health related quality of life
Dieterich, DT
Rodriguez-Torres, M
Rockstroh, JK
Lissen, E
Gonzalez-Garcia, J
Lazzarin, A
Carosi, G
Sasadeusz, J
Katlama, C
Montaner, J
Sette, H
Wintfeld, N
Green, J
Pate, KK
Torriani, FJ
XV INTERNATIONAL AIDS CONFERENCE: CLINICAL RESEARCH, TREATMENT, AND CARE, 2004, : 101 - 102
[27] RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS INFECTED WITH HCV GENOTYPE 1: INTERIM RESULTS FROM THE TriCo STUDY
Ferenci, P.
Flisiak, R.
Caruntu, F. A.
Lengyel, G.
Hohmann, M.
Bakalos, G.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S453 - S454
[28] Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study
Laguno, M.
Von Wichmann, M. A.
Van den Eynde, E.
Navarro, J.
Cifuentes, C.
Murillas, J.
Veloso, S.
Martinez-Rebollar, M.
Guardiola, J. M.
Jou, A.
Gomez-Sirvent, J. L.
Cervantes, M.
Pineda, J. A.
Lopez-Calvo, S.
Carrero, A.
Montes, M. L.
Deig, E.
Tapiz, A.
Ruiz-Mesa, J. D.
Cruceta, A.
de lazzari, E.
Mallolas, J.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 53 : 46 - 51
[29] Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV Co-infected patients: Follow up week 12 (SVR 12) interim results
Pol, S.
Cooper, C.
Fainboim, H.
Slim, J.
Rivero, A.
Laguno, M.
Thompson, S.
Wahl, J.
Greaves, W.
Sulkowski, Mark
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 15 - 15
[30] Efficacy of peginterferon alfa-2A and ribavirin in 2101 patients with HCV infection in real-life clinical practice: Results of the french hepatys study
Bourliere, Marc
Ouzan, Denis
Rosenheim, Michel
Doffoel, Michel
Marcellin, Patrick
Pawlotsky, Jean-Michel
Salomon, Laurence
Fagnani, Francis
Hayem, Cecile
Lonjon-Domanec, Isabelle
Vray, Muriel
HEPATOLOGY, 2007, 46 (04) : 366A - 366A

← 1 2 3 4 5 →